retatrutide experience nonalcoholic fatty liver disease trial Retatrutide in Canada: Clinical Results, Cost Expectations, and Patient Nonalcoholic fatty liver disease: Current – Retatrutide – new weight loss

Zhuo, P

Semaglutide slows the movement of food from the stomach into the small intestine, which prolongs the period during which the stomach remains physically full

Until now, the only GLP-1 medications for treating obesity were injectables: semaglutide (Wegovy) and tirzepatide (Zepbound)

112 Perez-GiraldoC.Cruz-VillalonG.Sanchez-SilosR.Martinez-RubioR.BlancoM

Abstract This study analyzed adverse events (AEs) of GLP-1RA and metformin combination therapy using FAERS data (20042024)

Some intestinal diseases, such as inflammatory bowel disease (IBD) or irritable bowel syndrome, can change the composition of the intestinal microbiota and affect the homeostasis of the intestinal carnitine pool